The study reveals SGLT-2is are linked to fewer COPD exacerbations in type 2 diabetes, suggesting a need for further clinical ...

Lilly will provide an initial payment to complete a Phase I trial of OLX75016, which started in February 2024.

Allurion’s CEO confirmed to Medical Device Network that the company has changed advertising, patient follow-up, and physician ...

Liraglutide, a GLP-1 significantly lowers the rate of recurrent stroke in patients with diabetes, with no apparent increase ...

In 2022, when the surge in popularity of the GLP-1 class of weight loss and diabetes drugs really began, stories of surprise ...

Results of a placebo-controlled trial support prior observational findings that GLP-1 agonists can help reduce alcohol ...

Administered as a once-weekly subcutaneous injection, Ozempic not only helps control blood glucose levels but also reduces ...

There’s no direct link between vision loss and taking the weight loss and diabetes drugs such as Ozempic, Wegovy, Mounjaro, ...

A new study adds to a growing body of research suggesting a potential link between popular GLP-1 medications like Ozempic and vision loss.

The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy.

Cash, cash equivalents, and restricted cash were $26.6M as of December 31, 2024 versus $24.9M as of September 30, 2024. “We are very excited ...

The beverage giant is ready to manage, mitigate and adjust to the “dynamic macro environment,” including potential tariffs ...